Topic:

Pipeline

Latest Headlines

Latest Headlines

Bristol-Myers takes a big step in its PD-1 lung cancer race with Merck

The FDA has accepted Bristol-Myers Squibb's application to get its star oncology treatment approved for lung cancer, setting up a speedy approval and putting the company first in line among drug developers at work in a blockbuster field.

Vitae slammed as another BACE inhibitor trips and Boehringer halts Alzheimer's study

Boehringer Ingelheim has put a hold on its Phase I work with a BACE inhibitor for Alzheimer's, marking the latest in a series of missteps for this category of therapeutics, which has emerged as one of the key arenas in the field.

Amgen completes PhIII trifecta as AMG416 goes head-to-head with Sensipar

Amgen hit the trifecta with a successful conclusion to its third, and last, Phase III study of AMG416, a new drug for secondary hyperparathyroidism which handily beat out its in-house rival Sensipar in a head-to-head study.

Ipsen picks up option to buy Canbex once PhIIa data rolls in

Ipsen has handed over €6 million ($6.8 million) for the option to buy British biotech Canbex Therapeutics.

Alkermes dumps its pain drug after a Phase I disappointment

Alkermes has pulled the plug on an abuse-deterrent pain medication after it came up short in early testing, pivoting its focus to some preclinical analgesics.

Lilly's new insulin is likely DOA after latest delay, analyst says

Eli Lilly's already-delayed new insulin has run into another roadblock, as potentially harmful liver side effects have sent the company back to the clinic, putting off a potential regulatory filing by a year or more and leading a top analyst to eulogize the program.

Merck bets big on NGM with a $450M handshake

Taking a page from famed partners like Sanofi and Regeneron and Roche and Genentech, Merck has signed a sweeping R&D deal with biotech NGM Biopharmaceuticals, promising up to $450 million for 5 years of pipeline-building collaboration.

Novo Nordisk's game-changing oral diabetes drug clears Phase II

Novo Nordisk's new oral diabetes drug measured up to its injected counterpart in a midstage study, promising results the company heralds as a milestone in the field.

Lilly delays its high-risk 'good' cholesterol trial with IMPROVE-IT in mind

Eli Lilly is extending its massive Phase III trial on a new cardio drug by 6 months in what the company says is a reaction to some recent developments in science.

Ferring bags PhIII assets to beef up orthopedic pipeline

Ferring Pharmaceuticals has snapped up the assets of BioSurface Engineering Technologies to add a pair of Phase III-ready orthopedic candidates to its pipeline. Both treatments are designed to improve bone repair.